• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
A case of recurrent fungemia and successful treatment with rezafungin.一例复发性真菌血症及使用瑞扎芬净成功治疗的病例。
IDCases. 2025 Apr 20;40:e02233. doi: 10.1016/j.idcr.2025.e02233. eCollection 2025.
2
Activity of a Long-Acting Echinocandin, Rezafungin, and Comparator Antifungal Agents Tested against Contemporary Invasive Fungal Isolates (SENTRY Program, 2016 to 2018).长效棘白菌素类药物雷扎芬净与其他抗真菌药物对当代侵袭性真菌分离株的活性检测(SENTRY 项目,2016 年至 2018 年)。
Antimicrob Agents Chemother. 2020 Mar 24;64(4). doi: 10.1128/AAC.00099-20.
3
Evaluation of Rezafungin Provisional CLSI Clinical Breakpoints and Epidemiological Cutoff Values Tested against a Worldwide Collection of Contemporaneous Invasive Fungal Isolates (2019 to 2020).评估 Rezafungin 的 CLSI 临时临床折点和流行病学 cutoff 值,该值针对来自全球范围的同期侵袭性真菌分离株进行了测试(2019 年至 2020 年)。
J Clin Microbiol. 2022 Apr 20;60(4):e0244921. doi: 10.1128/jcm.02449-21. Epub 2022 Mar 7.
4
Candida and candidaemia. Susceptibility and epidemiology.念珠菌与念珠菌血症。药敏性与流行病学。
Dan Med J. 2013 Nov;60(11):B4698.
5
Evaluation of the Post-Antifungal Effect of Rezafungin and Micafungin against Candida albicans, Candida parapsilosis and Candida glabrata.评估瑞他康唑和米卡芬净对白色念珠菌、近平滑念珠菌和光滑念珠菌的抗真菌后效应。
Mycoses. 2022 Nov;65(11):1040-1044. doi: 10.1111/myc.13490. Epub 2022 Jul 18.
6
Loss of C-5 Sterol Desaturase Activity Results in Increased Resistance to Azole and Echinocandin Antifungals in a Clinical Isolate of Candida parapsilosis.C-5 甾醇去饱和酶活性缺失导致临床分离近平滑念珠菌对唑类和棘白菌素类抗真菌药物的耐药性增加。
Antimicrob Agents Chemother. 2017 Aug 24;61(9). doi: 10.1128/AAC.00651-17. Print 2017 Sep.
7
Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations.棘白菌素类耐药性在光滑念珠菌中的增加:临床失败与 FKS 突变和最低抑菌浓度升高相关。
Clin Infect Dis. 2013 Jun;56(12):1724-32. doi: 10.1093/cid/cit136. Epub 2013 Mar 13.
8
Overcoming the Resistance Hurdle: Pharmacokinetic-Pharmacodynamic Target Attainment Analyses for Rezafungin (CD101) against Candida albicans and Candida glabrata.克服耐药障碍:瑞他康唑(CD101)对白色念珠菌和光滑念珠菌的药代动力学-药效学目标达成分析。
Antimicrob Agents Chemother. 2018 May 25;62(6). doi: 10.1128/AAC.02614-17. Print 2018 Jun.
9
EUCAST Reference Testing of Rezafungin Susceptibility and Impact of Choice of Plastic Plates.EUCAST 对雷沙康唑敏感性的参考检测以及塑料板选择的影响。
Antimicrob Agents Chemother. 2019 Aug 23;63(9). doi: 10.1128/AAC.00659-19. Print 2019 Sep.
10
Rezafungin Activity against Contemporary Nordic Clinical Isolates and Determined by the EUCAST Reference Method.雷沙康唑对北欧临床分离株的活性及 EUCAST 参考方法的测定。
Antimicrob Agents Chemother. 2020 Mar 24;64(4). doi: 10.1128/AAC.02438-19.

引用本文的文献

1
A Review of Current Insights in Fungal Endocarditis.真菌性心内膜炎的当前见解综述
J Clin Med. 2025 Aug 30;14(17):6149. doi: 10.3390/jcm14176149.

本文引用的文献

1
Candida Infective Endocarditis in Patients With Candida spp. Bloodstream Infection: Risk Factors and 1- Year Mortality.念珠菌属血流感染患者的念珠菌感染性心内膜炎:危险因素及1年死亡率
Mycoses. 2025 Feb;68(2):e70032. doi: 10.1111/myc.70032.
2
Safety of rezafungin as a long-term treatment option in two patients with complicated fungal infections: two cases from Lecco Hospital (Italy).两名复杂性真菌感染患者长期应用瑞沙康唑治疗的安全性:来自意大利莱科医院的 2 个病例。
Antimicrob Agents Chemother. 2024 Aug 7;68(8):e0075024. doi: 10.1128/aac.00750-24. Epub 2024 Jul 12.
3
Treatment of native valve endocarditis with rezafungin: a case report.用瑞扎芬净治疗天然瓣膜性心内膜炎:一例报告。
JAC Antimicrob Resist. 2024 Mar 12;6(2):dlae042. doi: 10.1093/jacamr/dlae042. eCollection 2024 Apr.
4
Fungal Endocarditis: Pathophysiology, Epidemiology, Clinical Presentation, Diagnosis, and Management.真菌性心内膜炎:病理生理学、流行病学、临床表现、诊断和治疗。
Clin Microbiol Rev. 2023 Sep 21;36(3):e0001923. doi: 10.1128/cmr.00019-23. Epub 2023 Jul 13.
5
Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial.瑞扎芬净与卡泊芬净治疗念珠菌血症和侵袭性念珠菌病的疗效比较(ReSTORE):一项多中心、双盲、双模拟、随机3期试验。
Lancet. 2023 Jan 7;401(10370):49-59. doi: 10.1016/S0140-6736(22)02324-8. Epub 2022 Nov 25.
6
Clinical features, diagnosis and treatment outcome of fungal endocarditis: A systematic review of reported cases.真菌性心内膜炎的临床特征、诊断和治疗结果:系统综述报道病例。
Mycoses. 2022 Mar;65(3):294-302. doi: 10.1111/myc.13398. Epub 2021 Dec 3.
7
Population-Based Active Surveillance for Culture-Confirmed Candidemia - Four Sites, United States, 2012-2016.基于人群的培养确诊念珠菌血症主动监测-四个地点,美国,2012-2016 年。
MMWR Surveill Summ. 2019 Sep 27;68(8):1-15. doi: 10.15585/mmwr.ss6808a1.
8
Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.《念珠菌病管理临床实践指南:美国传染病学会2016年更新版》
Clin Infect Dis. 2016 Feb 15;62(4):e1-50. doi: 10.1093/cid/civ933. Epub 2015 Dec 16.
9
Mechanisms of Antifungal Drug Resistance.抗真菌药物耐药机制
Cold Spring Harb Perspect Med. 2014 Nov 10;5(7):a019752. doi: 10.1101/cshperspect.a019752.
10
Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-year analysis of susceptibilities of Candida Species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion.ARTEMIS DISK 全球抗真菌监测研究结果,1997 年至 2007 年:10.5 年时间内通过 CLSI 标准化纸片扩散法测定的念珠菌属对氟康唑和伏立康唑的药敏性分析。
J Clin Microbiol. 2010 Apr;48(4):1366-77. doi: 10.1128/JCM.02117-09. Epub 2010 Feb 17.

一例复发性真菌血症及使用瑞扎芬净成功治疗的病例。

A case of recurrent fungemia and successful treatment with rezafungin.

作者信息

Chandramohan Divya, Aguilar Samantha, Gawrys Gerard, Wiederhold Nathan P, Traugott Kristi, Patterson Thomas F

机构信息

Division of Infectious Diseases, Department of Medicine, University of Texas Health, San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78229, United States.

Department of Pharmacotherapy and Pharmacy Services, University of Texas Health, San Antonio, 4502 Medical Drive, San Antonio, TX 78229, United States.

出版信息

IDCases. 2025 Apr 20;40:e02233. doi: 10.1016/j.idcr.2025.e02233. eCollection 2025.

DOI:10.1016/j.idcr.2025.e02233
PMID:40330580
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12051642/
Abstract

Antifungal resistance in can develop to different classes of drugs, including the azoles and echinocandins. This organism is known to cause infective endocarditis with a particular predilection for prosthetic valves. Herein we present a case of recurrent fungemia with in a middle-aged woman with Tetralogy of Fallot who had a right ventricle to pulmonary artery conduit, and a transcatheter pulmonary valve replacement in the past. Her isolate showed increasing minimum inhibitory concentrations (MIC) to various antifungals with higher MICs to azoles, including resistance to fluconazole, resulting in limited treatment options. She had affliction of her prosthetic pulmonic valve with and was treated with the second-generation echinocandin, rezafungin, for six months. This case illustrates the tolerability profile of long-term treatment with rezafungin.

摘要

[具体菌种名称]的耐药性可能发展至对不同种类药物产生抗性,包括唑类和棘白菌素类。已知该菌可引起感染性心内膜炎,对人工瓣膜有特别的偏好。在此,我们报告一例患有法洛四联症的中年女性复发性真菌血症病例,该患者曾行右心室至肺动脉导管术,并于过去进行过经导管肺动脉瓣置换术。她的分离菌株对多种抗真菌药物的最低抑菌浓度(MIC)不断增加,对唑类药物的MIC更高,包括对氟康唑耐药,导致治疗选择有限。她的人工肺动脉瓣受到[具体菌种名称]感染,接受了第二代棘白菌素类药物瑞扎芬净治疗六个月。本病例说明了瑞扎芬净长期治疗的耐受性情况。